Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer.

Collina F, Aquino G, Brogna M, Cipolletta S, Buonfanti G, De Laurentiis M, Di Bonito M, Cantile M, Botti G.

J Cancer. 2019 May 12;10(9):2018-2024. doi: 10.7150/jca.29670. eCollection 2019.

2.

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.

Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribecco AS, Putzu C, Del Mastro L, Rossi E, Tinessa V, Mosconi AM, Nuzzo F, Di Rella F, Gravina A, Iodice G, Landi G, Pacilio C, Forestieri V, Lauria R, Fabbri A, Ibrahim T, De Maio E, Barni S, Gori S, Simeon V, Arenare L, Daniele G, Piccirillo MC, Normanno N, de Matteis A, Gallo C.

Eur J Cancer. 2019 Jun 1. pii: S0959-8049(19)30297-7. doi: 10.1016/j.ejca.2019.05.004. [Epub ahead of print]

PMID:
31164265
3.

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.

Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, Monti MG, Iaffaioli RV, De Laurentiis M, Ascierto PA, Botti G, De Lorenzo C, Maurea N.

Int J Cardiol. 2019 May 17. pii: S0167-5273(18)37531-4. doi: 10.1016/j.ijcard.2019.05.028. [Epub ahead of print]

PMID:
31160077
4.

Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?

Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, Corvaja C, Arpino G, Del Mastro L, De Placido S, De Laurentiis M, Cristofanilli M, Puglisi F.

Cancer Treat Rev. 2019 Feb;73:73-83. doi: 10.1016/j.ctrv.2019.01.004. Epub 2019 Jan 11. Review.

PMID:
30682661
5.

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.

Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, Arpino G, De Laurentiis M, Puglisi F, De Placido S, Del Mastro L.

Front Oncol. 2018 Dec 12;8:608. doi: 10.3389/fonc.2018.00608. eCollection 2018. Review.

6.

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P.

Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518.

PMID:
30475947
7.

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.

Pelizzari G, Arpino G, Biganzoli L, Cinieri S, De Laurentiis M, Del Mastro L, Di Leo A, Gori S, Guarneri V, Marchetti P, Puglisi F.

BMC Cancer. 2018 Sep 27;18(1):932. doi: 10.1186/s12885-018-4843-2.

8.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J.

Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18.

PMID:
30241001
9.

Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.

Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA.

Oncologist. 2018 Oct;23(10):1137-1143. doi: 10.1634/theoncologist.2018-0065. Epub 2018 Jul 17.

PMID:
30018134
10.

Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.

De Laurentiis M, Bonfadini C, Lorusso V, Cilenti G, Di Rella F, Altavilla G, Otero M, Ardizzoia A, Marchetti P, Peverelli G, Amoroso D, Vecchio S, Fiorio E, Orecchia S.

Support Care Cancer. 2018 Dec;26(12):4021-4029. doi: 10.1007/s00520-018-4259-1. Epub 2018 Jun 25.

PMID:
29943152
11.

Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.

Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G.

Cancer Treat Rev. 2018 Jul;68:102-110. doi: 10.1016/j.ctrv.2018.06.005. Epub 2018 Jun 11. Review.

12.

Active lifestyles in older adults: an integrated predictive model of physical activity and exercise.

Galli F, Chirico A, Mallia L, Girelli L, De Laurentiis M, Lucidi F, Giordano A, Botti G.

Oncotarget. 2018 May 22;9(39):25402-25413. doi: 10.18632/oncotarget.25352. eCollection 2018 May 22.

13.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G.

J Clin Oncol. 2018 Aug 20;36(24):2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3.

PMID:
29860922
14.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.

Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.

PMID:
29804902
15.

Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey.

Bonotto M, Basile D, Gerratana L, Pelizzari G, Bartoletti M, Vitale MG, Fanotto V, Lisanti C, Mansutti M, Minisini AM, Aprile G, De Laurentiis M, Montemurro F, Del Mastro L, Puglisi F.

Breast. 2018 Aug;40:45-52. doi: 10.1016/j.breast.2018.04.011. Epub 2018 Apr 19.

PMID:
29679936
16.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
17.

Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study.

Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, Pensabene M, De Laurentiis M, Augustin LSA, Amore A, D'Aiuto M, Tortoriello R, Accurso A, Cavalcanti E, Botti G, Montella M, De Placido S, Arpino G.

Oncotarget. 2017 Dec 5;8(70):115709-115717. doi: 10.18632/oncotarget.22977. eCollection 2017 Dec 29.

18.

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.

De Angelis C, Di Maio M, Crispo A, Giuliano M, Schettini F, Bonotto M, Gerratana L, Iacono D, Cinausero M, Riccardi F, Ciancia G, De Laurentiis M, Puglisi F, De Placido S, Arpino G.

Oncotarget. 2017 Nov 24;8(68):112816-112824. doi: 10.18632/oncotarget.22643. eCollection 2017 Dec 22.

19.

Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells.

Ambrosio MR, D'Esposito V, Costa V, Liguoro D, Collina F, Cantile M, Prevete N, Passaro C, Mosca G, De Laurentiis M, Di Bonito M, Botti G, Franco R, Beguinot F, Ciccodicola A, Formisano P.

Oncotarget. 2017 Nov 20;8(65):109000-109017. doi: 10.18632/oncotarget.22552. eCollection 2017 Dec 12.

20.

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.

De Placido S, Giuliano M, Schettini F, Von Arx C, Buono G, Riccardi F, Cianniello D, Caputo R, Puglisi F, Bonotto M, Fabi A, Bilancia D, Ciccarese M, Lorusso V, Michelotti A, Bruzzese D, Veneziani BM, Locci M, De Laurentiis M, Arpino G.

Breast. 2018 Apr;38:86-91. doi: 10.1016/j.breast.2017.12.012. Epub 2018 Jan 4.

PMID:
29287189
21.

An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer.

Polo A, Nittoli C, Crispo A, Langastro T, Cocco S, Severino L, De Laurentiis M, Ciliberto G, Montella M, Budillon A, Costantini S.

Mol Biosyst. 2017 Nov 21;13(12):2687-2696. doi: 10.1039/c7mb00489c.

PMID:
29072741
22.

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F.

Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8.

23.

High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients.

Alviggi C, Marci R, Vallone R, Conforti A, Di Rella F, Strina I, Picarelli S, De Rosa P, De Laurentiis M, Yding Andersen C, De Placido G.

Eur Rev Med Pharmacol Sci. 2017 Jul;21(13):3134-3138.

24.

Self-Efficacy for Coping with Cancer Enhances the Effect of Reiki Treatments During the Pre-Surgery Phase of Breast Cancer Patients.

Chirico A, D'Aiuto G, Penon A, Mallia L, DE Laurentiis M, Lucidi F, Botti G, Giordano A.

Anticancer Res. 2017 Jul;37(7):3657-3665.

PMID:
28668857
25.

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.

Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.

PMID:
28625777
26.

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M.

Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30. Erratum in: Lancet Oncol. 2019 Feb;20(2):e71-e72.

27.

Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.

Caputo R, Cianniello D, De Laurentiis M.

Future Oncol. 2017 Apr;13(11s):45-50. doi: 10.2217/fon-2016-0516.

PMID:
28481184
28.

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

Aapro M, De Laurentiis M, Rea D, Bargallo Rocha JE, Elizalde R, Landherr L, Linderholm B, Mamounas E, Markopoulos C, Neven P, Petrovsky A, Rouzier R, Smit V, Svedman C, Schneider D, Thomssen C, Martin M.

Breast. 2017 Jun;33:191-199. doi: 10.1016/j.breast.2017.01.012. Epub 2017 Apr 22.

PMID:
28441617
29.

Self-efficacy for Coping Moderates the Effects of Distress on Quality of Life in Palliative Cancer Care.

Chirico A, Serpentini S, Merluzzi T, Mallia L, Del Bianco P, Martino R, Trentin L, Bucci E, DE Laurentiis M, Capovilla E, Lucidi F, Botti G, Giordano A.

Anticancer Res. 2017 Apr;37(4):1609-1615.

PMID:
28373421
30.

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.

Botti G, Collina F, Scognamiglio G, Rao F, Peluso V, De Cecio R, Piezzo M, Landi G, De Laurentiis M, Cantile M, Di Bonito M.

Int J Mol Sci. 2017 Feb 21;18(2). pii: E459. doi: 10.3390/ijms18020459.

31.

Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.

De Placido S, De Angelis C, Giuliano M, Pizzi C, Ruocco R, Perrone V, Bruzzese D, Tommasielli G, De Laurentiis M, Cammarota S, Arpino G, Arpino G.

Br J Cancer. 2017 Mar 14;116(6):821-827. doi: 10.1038/bjc.2017.24. Epub 2017 Feb 7.

32.

Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial.

Augustin LS, Libra M, Crispo A, Grimaldi M, De Laurentiis M, Rinaldo M, D'Aiuto M, Catalano F, Banna G, Ferrau' F, Rossello R, Serraino D, Bidoli E, Massarut S, Thomas G, Gatti D, Cavalcanti E, Pinto M, Riccardi G, Vidgen E, Kendall CW, Jenkins DJ, Ciliberto G, Montella M.

BMC Cancer. 2017 Jan 23;17(1):69. doi: 10.1186/s12885-017-3064-4.

33.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.

Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10.

PMID:
27951450
34.

Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e19-e26. Review.

PMID:
27755239
35.

Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.

Sini V, Cassano A, Corsi D, De Laurentiis M, Gamucci T, Mauri M, Naso G, Roselli M, Ruggeri EM, Tonini G, Vici P, Zampa G, Marchetti P.

Tumori. 2016 Oct 13;102(5):472-480. doi: 10.5301/tj.5000555. Epub 2016 Aug 23. Review.

PMID:
27647231
36.

Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes.

Crispo A, Augustin LS, Grimaldi M, Nocerino F, Giudice A, Cavalcanti E, Di Bonito M, Botti G, De Laurentiis M, Rinaldo M, Esposito E, Riccardi G, Amore A, Libra M, Ciliberto G, Jenkins DJ, Montella M.

J Cell Physiol. 2017 May;232(5):1144-1150. doi: 10.1002/jcp.25579. Epub 2016 Sep 30.

PMID:
27579809
37.

Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S19-26. doi: 10.2459/JCM.0000000000000377. Review.

PMID:
27183521
38.

Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.

Crispo A, Montella M, Buono G, Grimaldi M, D'Aiuto M, Capasso I, Esposito E, Amore A, Nocerino F, Augustin LS, Giudice A, Di Bonito M, Giuliano M, Forestieri V, De Laurentiis M, Rinaldo M, Ciliberto G, De Placido S, Arpino G.

Curr Res Transl Med. 2016 Jan-Mar;64(1):15-20. doi: 10.1016/j.retram.2016.01.004. Epub 2016 Mar 2.

PMID:
27140595
39.

Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5.

D'Esposito V, Liguoro D, Ambrosio MR, Collina F, Cantile M, Spinelli R, Raciti GA, Miele C, Valentino R, Campiglia P, De Laurentiis M, Di Bonito M, Botti G, Franco R, Beguinot F, Formisano P.

Oncotarget. 2016 Apr 26;7(17):24495-509. doi: 10.18632/oncotarget.8336.

40.

Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice.

Sini V, Cinieri S, Conte P, De Laurentiis M, Leo AD, Tondini C, Marchetti P.

Crit Rev Oncol Hematol. 2016 Apr;100:57-68. doi: 10.1016/j.critrevonc.2016.02.008. Epub 2016 Feb 18. Review.

PMID:
26944782
41.

Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohort.

D'Aiuto M, Chirico A, De Riggi MA, Frasci G, De Laurentiis M, Di Bonito M, Vici P, Pizzuti L, Sergi D, Maugeri-Saccà M, Barba M, Giordano A.

Cancer Biol Ther. 2016 May 3;17(5):470-6. doi: 10.1080/15384047.2016.1156265. Epub 2016 Mar 2.

42.

Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.

Montemurro F, Del Mastro L, De Laurentiis M, Puglisi F.

Expert Rev Anticancer Ther. 2016;16(2):211-8. doi: 10.1586/14737140.2016.1128327. Epub 2015 Dec 23. Review.

PMID:
26634955
43.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S.

J Cancer Res Clin Oncol. 2016 Mar;142(3):669-78. doi: 10.1007/s00432-015-2033-z. Epub 2015 Aug 25.

PMID:
26531187
44.

Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer.

Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M, Nuzzo F, Cantile M, Botti G.

Biomed Res Int. 2015;2015:158682. doi: 10.1155/2015/158682. Epub 2015 Oct 4.

45.

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy.

Arpino G, De Angelis C, Buono G, Colao A, Giuliano M, Malgieri S, Cicala S, De Laurentiis M, Accurso A, Crispo A, Limite G, Lauria R, Veneziani BM, Forestieri V, Bruzzese D, De Placido S.

Breast Cancer Res Treat. 2015 Nov;154(1):127-32. doi: 10.1007/s10549-015-3586-x. Epub 2015 Sep 30.

46.

The role of taxanes in triple-negative breast cancer: literature review.

Mustacchi G, De Laurentiis M.

Drug Des Devel Ther. 2015 Aug 5;9:4303-18. doi: 10.2147/DDDT.S86105. eCollection 2015. Review. Erratum in: Drug Des Devel Ther. 2015;9:5669.

47.

Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis.

Cabula C, Campana LG, Grilz G, Galuppo S, Bussone R, De Meo L, Bonadies A, Curatolo P, De Laurentiis M, Renne M, Valpione S, Fabrizio T, Solari N, Guida M, Santoriello A, D'Aiuto M, Agresti R.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S442-50. doi: 10.1245/s10434-015-4779-6. Epub 2015 Aug 5.

48.

Virtual Reality in Health System: Beyond Entertainment. A Mini-Review on the Efficacy of VR During Cancer Treatment.

Chirico A, Lucidi F, De Laurentiis M, Milanese C, Napoli A, Giordano A.

J Cell Physiol. 2016 Feb;231(2):275-87. doi: 10.1002/jcp.25117. Review.

PMID:
26238976
49.

Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?

Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M.

Eur J Surg Oncol. 2015 Oct;41(10):1288-92. doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. Review.

PMID:
26238477
50.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators.

Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.

PMID:
25740286

Supplemental Content

Loading ...
Support Center